Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › nivolumab

nivolumab

61 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of nivolumab

285 trials tracked of nivolumab: 50 in phase 3 or 4 and 35 with published results. The most-cited published study has 3703 citations.

285Trials tracked
50Phase 3 & 4
0Recruiting
35With published results
Phase distribution
Phase 4 4 Phase 3 46 Phase 2 207 Phase 1 25 Other / NA 3
  1. Phase 3 Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) Completed · 3,703 cited
  2. Phase 3 An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) Completed · 2,820 cited
  3. Phase 3 An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Completed · 2,607 cited
  4. Phase 3 An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer Completed · 1,844 cited
  5. Phase 3 A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients Completed · 1,506 cited
  6. Phase 3 A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC Completed · 1,354 cited
Show 44 more trials
  1. Phase 3 A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin Completed · 1,240 cited
  2. Phase 3 Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer Completed · 1,218 cited
  3. Phase 3 Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients Completed · 1,210 cited
  4. Phase 3 An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma Completed · 1,099 cited
  5. Phase 3 Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) Completed · 804 cited
  6. Phase 3 Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017) Completed · 659 cited
  7. Phase 3 An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) Completed · 539 cited
  8. Phase 3 An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) Completed · 525 cited
  9. Phase 3 Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer Completed · 357 cited
  10. Phase 3 An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy Completed · 273 cited
  11. Phase 3 Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) Completed · 261 cited
  12. Phase 3 Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer Completed · 256 cited
  13. Phase 3 A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) Completed · 251 cited
  14. Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) Completed · 240 cited
  15. Phase 3 A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney Completed · 193 cited
  16. Phase 3 A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Completed · 190 cited
  17. Phase 3 An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma Completed · 174 cited
  18. Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed · 171 cited
  19. Phase 3 A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy Completed · 165 cited
  20. Phase 4 A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer Completed · 142 cited
  21. Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer Completed · 122 cited
  22. Phase 3 A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma Completed · 83 cited
  23. Phase 3 An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread Completed · 74 cited
  24. Phase 3 A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery Completed · 46 cited
  25. Phase 3 Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma Completed · 32 cited
  26. Phase 3 Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma Completed · 31 cited
  27. Phase 3 Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma Completed · 27 cited
  28. Phase 3 A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer Completed · 5 cited
  29. Phase 3 A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma Completed · 2 cited
  30. Phase 4 An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Completed
  31. Phase 4 Study of Nivolumab for Advanced Cancers in India Completed
  32. Phase 4 A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India Completed
  33. Phase 3 Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer Completed
  34. Phase 3 A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks Completed
  35. Phase 3 An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma Completed
  36. Phase 3 Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer Completed
  37. Phase 3 An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma Completed
  38. Phase 3 Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Completed
  39. Phase 3 A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer Completed
  40. Phase 3 A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia Completed
  41. Phase 3 Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Completed
  42. Phase 3 A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer Completed
  43. Phase 3 A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection Completed
  44. Phase 3 Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC Completed

Showing the 50 most-cited and recently-updated of 285 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Gut microbiome taxa and metabolites enhance immune checkpoint inhibitor efficacy and mitigate systemic toxicity
Oncology Sys. Review
Gut microbiome taxa and metabolites enhance immune checkpoint inhibitor efficacy and mitigate systemic toxicity Gut bacteria may improve cancer treatment and reduce side effects
This systematic review examines the role of gut microbiota, including specific taxa like Bacteroides and Akkermansia muciniphila, in modulat…
Specific gut bacteria and their byproducts could help cancer treatments work better while protecting the heart and colon from inflammation.
Frontiers Jul 14, 2026
Adjuvant PD-1 inhibitors significantly improve disease-free survival in patients with resected high-risk muscle-invasive bladder cancer
Urology Meta-analysis
Adjuvant PD-1 inhibitors significantly improve disease-free survival in patients with resected high-risk muscle-invasive bladder cancer PD-1 Inhibitors Improve Survival for Muscle Invasive Bladder Cancer
This meta-analysis of Phase 3 trials indicates that adjuvant nivolumab or pembrolizumab improves disease-free survival (DFS) in patients wit…
New data suggests that PD-1 inhibitors like nivolumab or pembrolizumab may improve disease-free survival for patients with high-risk bladder…
Jul 5, 2026
Nivolumab plus chemotherapy improves pathological complete response in resectable NSCLC with PD-L1 < 1%
Pulmonology & Critical Care Sys. Review
Nivolumab plus chemotherapy improves pathological complete response in resectable NSCLC with PD-L1 < 1% Nivolumab plus chemotherapy improves pathological response in certain lung cancers
This network meta-analysis of 1012 patients with resectable non-small cell lung cancer (NSCLC) and PD-L1 expression < 1% found that nivoluma…
A new analysis shows that adding nivolumab to chemotherapy can improve specific cancer responses for patients with low PD-L1 levels.
Jul 4, 2026
Novel agent-based regimens provide superior efficacy and lower toxicity than traditional chemotherapy in older adults
Oncology Meta-analysis
Novel agent-based regimens provide superior efficacy and lower toxicity than traditional chemotherapy in older adults New Treatments Show Better Results for Older Adults with Hodgkin Lymphoma
This meta-analysis of 568 patients with classic Hodgkin lymphoma found that novel agent-based regimens, including Brentuximab Vedotin and PD…
Newer treatments like Brentuximab Vedotin and nivolumab show better results and fewer side effects than traditional chemotherapy for older a…
Jul 3, 2026
Elevated troponin levels are associated with increased risk of MACE and all-cause mortality in ICI-associated myocarditis
Cardiology Meta-analysis
Elevated troponin levels are associated with increased risk of MACE and all-cause mortality in ICI-associated myocarditis Troponin levels help identify heart inflammation in cancer patients
This meta-analysis evaluates the performance of cardiac troponin as a biomarker for identifying immune checkpoint inhibitor (ICI)-associated…
A new look at cardiac troponin shows it can help doctors spot and predict serious heart risks for patients on certain cancer treatments.
Frontiers Jun 26, 2026
Immune-based combinations show superior overall survival compared to sorafenib in advanced hepatocellular carcinoma
Drug Pipeline Meta-analysis
Immune-based combinations show superior overall survival compared to sorafenib in advanced hepatocellular carcinoma New data shows better survival for liver cancer patients
This systematic review and network meta-analysis of 8,138 patients evaluated immune-based combinations versus monotherapies for advanced hep…
New research highlights how specific immune-based drug combinations can improve survival rates for people with advanced liver cancer.
Frontiers Jun 13, 2026
Undetectable baseline ctDNA significantly improves progression-free and overall survival in advanced NSCLC patients
Drug Pipeline Meta-analysis
Undetectable baseline ctDNA significantly improves progression-free and overall survival in advanced NSCLC patients Tumor DNA Levels Help Predict Outcomes in Lung Cancer Treatment
This meta-analysis of 2,107 patients evaluates the role of circulating tumor DNA (ctDNA) as a biomarker for outcomes in advanced NSCLC treat…
Testing for circulating tumor DNA may help doctors predict how well patients with advanced lung cancer respond to immunotherapy treatments.
Frontiers Jun 13, 2026
Lenvatinib plus PD-1 inhibitor improves survival versus bevacizumab plus PD-1 inhibitor in unresectable hepatocellular carcinoma
Oncology Meta-analysis
Lenvatinib plus PD-1 inhibitor improves survival versus bevacizumab plus PD-1 inhibitor in unresectable hepatocellular carcinoma Meta-analysis shows lenvatinib-based regimens improve survival for unresectable liver cancer in East Asia
This systematic review and meta-analysis evaluated first-line treatment for unresectable hepatocellular carcinoma in East Asian populations.
A meta-analysis of East Asian patients with unresectable liver cancer found lenvatinib-based regimens improved survival compared to bevacizu…
Jun 4, 2026
PD-1/PD-L1 inhibitors plus chemotherapy improve survival in advanced endometrial cancer
Allergy & Immunology Meta-analysis
PD-1/PD-L1 inhibitors plus chemotherapy improve survival in advanced endometrial cancer Immunotherapy combo extends life in advanced endometrial cancer
A meta-analysis of 4,052 patients from RCTs found that adding PD-1/PD-L1 inhibitors to chemotherapy improved overall survival (median 43.7 v…
Adding immunotherapy to chemo boosted survival by over 14 months in advanced endometrial cancer, a new analysis finds.
Frontiers Jun 2, 2026
Nivolumab monotherapy yielded 12-month progression-free survival in metastatic anaplastic thyroid cancer
Oncology Sys. Review
Nivolumab monotherapy yielded 12-month progression-free survival in metastatic anaplastic thyroid cancer Off-label immunotherapy may help some patients with metastatic anaplastic thyroid cancer
This case report describes a 76-year-old female with metastatic anaplastic thyroid cancer treated with off-label nivolumab monotherapy. The …
A single case report suggests off-label nivolumab helped a 76-year-old woman live longer with metastatic anaplastic thyroid cancer.
Frontiers Jun 2, 2026
Cutaneous immune-related adverse events associated with improved progression-free survival in non-small cell lung cancer
Pulmonology & Critical Care Meta-analysis
Cutaneous immune-related adverse events associated with improved progression-free survival in non-small cell lung cancer Skin reactions in lung cancer patients may signal longer life with certain treatments
This meta-analysis evaluated patients with non-small cell lung cancer receiving anti-PD-1, PD-L1, or chemotherapy. The analysis found that c…
A large review found that specific skin reactions linked to cancer drugs are connected to longer survival times for some lung cancer patient…
Jun 1, 2026
PD-1/PD-L1 inhibitors improve response in dMMR/MSI-H metastatic colorectal cancer
Oncology Meta-analysis
PD-1/PD-L1 inhibitors improve response in dMMR/MSI-H metastatic colorectal cancer New meta-analysis shows PD-1 inhibitors improve response rates for dMMR colorectal cancer
This meta-analysis of 1460 patients with dMMR/MSI-H metastatic colorectal cancer found that PD-1/PD-L1 monotherapy significantly improved ob…
A large review of 1460 patients found PD-1 inhibitors significantly improved tumor response rates compared to chemotherapy for dMMR colorect…
May 22, 2026